Gut Microbiota Diversity and CompositionGUTSNCT07864779
Effects of Barley and Kefir on Gut Microbiota in Physically Active Adults
A study testing Barley and Kefir in people with Gut Microbiota Diversity and Composition and Gut Microbiota Modulation, run by Western Norway University of Applied Sciences at 1 site in Norway.
Trial summary
The purpose of this randomized controlled clinical trial is to investigate whether a four-week dietary intervention consisting of a daily meal with barley and kefir can influence gut microbiota diversity and composition in physically active adults participating in endurance sports. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Gut Microbiota Diversity and Composition, Gut Microbiota Modulation, Probiotic
- What is being tested?
- Barley and Kefir
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteNorway
- Study dates
- 7 Sep 2026to Jun 2031
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Adults aged 18 - 55 years
- High aerobic capacity defined by the following minimum estimated VO₂max values:
- Men:
- 20-29 years: ≥ 51 mL/kg/min
- 30-39 years: ≥ 47 mL/kg/min
- 40-49 years: ≥ 43 mL/kg/min
Show all 12Show fewer
- 50-55 years: ≥ 38 mL/kg/min
- Women:
- 20-29 years: ≥ 44 mL/kg/min
- 30-39 years: ≥ 40 mL/kg/min
- 40-49 years: ≥ 36 mL/kg/min
- 50-55 years: ≥ 32 mL/kg/min
Who cannot join
- Pregnancy
- Ulcerative colitis
- Crohn's disease
- Coeliac disease
- Milk allergy
- Lactose intolerance
- Use of antibiotics within the previous 6 months
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Norway1 site, 1 recruiting
- Recruiting
Western Norway University of Applied Sciences
Bergen, 5225
Iselin T Vildmyren, PhD, +47 55 58 72 04, isvi@hvl.no
About this study
Official title: Effects of a Four-Week Dietary Intervention With Barley and Kefir on Gut Microbiota, Circulating Metabolites, and Health Outcomes in Physically Active Adults: A Randomized Controlled Trial
The purpose of this randomized controlled clinical trial is to investigate whether a four-week dietary intervention consisting of a daily meal with barley and kefir can influence gut microbiota diversity and composition in physically active adults participating in endurance sports. The study will further examine whether diet-induced changes in the gut microbiota are associated with changes in relevant circulating and urinary metabolites.
Growing evidence indicates that the gut microbiota plays an important role in metabolism, immune function, and overall health. Dietary factors are among the most important modulators of gut microbial composition. Barley contains dietary fibre including beta-glucans and other prebiotic components that may promote the growth of beneficial bacteria, while kefir contains live probiotic lactic acid bacteria that may influence both microbial composition and function. However, there is limited knowledge regarding how practical and realistic dietary interventions affect gut microbiota and host biological responses in physically active adults.
Read more
The primary objectives of the study are to determine whether daily consumption of a standardized meal consisting of barley porridge (70 g) and kefir (200 mL) for four weeks alters gut microbiota alpha diversity and gut microbiota composition compared with maintaining a habitual diet.
Secondary objectives are to investigate whether changes in gut microbiota are associated with changes in circulating and urinary metabolite profiles related to gut microbiota activity and energy metabolism.
Physically active participants aged 18 to 55 will be recruited and randomized to either an intervention group or a control group. Participants assigned to the intervention group will consume a daily breakfast consisting of barley porridge and kefir for four weeks. Participants assigned to the control group will maintain their habitual diet without receiving the dietary intervention. Both groups will be asked to maintain their usual dietary practices and training routines throughout the study period.
Data collection will be performed at baseline and after four weeks and will include stool samples, blood samples, urine samples, dietary interviews, and recording of training volume and training load. Stool samples will be analyzed using Precision Microbiome Profiling (PMP) to characterize gut microbiota diversity and composition. Blood and urine samples will be analyzed using metabolomics approaches to assess circulating and urinary metabolites.
The study aims to provide a comprehensive understanding of the relationships among diet, gut microbiota, metabolite profiles, and cellular responses in physically active adults, and to generate new knowledge regarding biological mechanisms that may be relevant for health, recovery, and physical performance.
Read the detailed description
The human gut microbiota is increasingly recognized as an important contributor to metabolic regulation, immune function, and overall health. A diverse and functionally balanced gut microbiota has been associated with favourable metabolic and health outcomes, while alterations in microbial composition have been linked to a range of physiological and pathological conditions. Emerging evidence suggests that the gut microbiota may also play a role in biological processes relevant to exercise adaptation, recovery, and physical performance.
Physically active individuals participating in endurance sports may represent a particularly interesting population for microbiome research. Previous studies suggest that highly trained individuals can exhibit distinct gut microbiota profiles compared with less active populations. At the same time, considerable inter-individual variation exists, and further research is needed to better understand how dietary factors may influence gut microbiota composition and function in this population.
Diet is one of the most important determinants of gut microbiota composition. The present study focuses on a practical dietary strategy based on two commonly available food products with potential microbiota-modulating properties. Barley is rich in dietary fibre, including beta-glucans and other prebiotic components that may stimulate the growth and metabolic activity of beneficial gut microbiota. Kefir is a fermented dairy product containing probiotic lactic acid bacteria and other microorganisms that may influence microbial composition and function. Both foods have demonstrated biological effects in previous studies and represent a realistic dietary intervention with potential applicability beyond a research setting.
The study is designed as a randomized controlled parallel-group intervention trial. Participants will be randomly allocated to either an intervention group or a control group using sex-stratified randomization to ensure balanced representation of men and women across study groups. The intervention group will consume a standardized breakfast consisting of barley porridge (70 g dry weight) and kefir (200 mL) daily for four weeks. Participants assigned to the control group will continue their habitual diet without receiving the dietary intervention. All participants will be asked to maintain their usual dietary habits and training routines throughout the study period.
Gut microbiota will be characterized using Precision Microbiome Profiling (PMP), a quantitative PCR-based analytical platform capable of quantifying approximately 100 microbial taxa representative of the human gut microbiome. Analyses will focus on changes in alpha diversity, assessed by the Shannon Diversity Index, as well as changes in the relative abundance of selected bacterial taxa.
Blood and urine samples will be analysed using metabolomics approaches to characterize metabolites associated with gut microbial activity and energy metabolism. Particular attention will be given to metabolites that may reflect interactions between the gut microbiota and host physiology. As gut microbiota-derived metabolites can enter the systemic circulation and act as signalling molecules between microbial communities and host tissues, metabolite profiling may contribute to a better understanding of potential biological mechanisms linking dietary intake, microbial activity, and systemic metabolism.
Data collection will be performed at baseline and after four weeks. Biological sampling will include stool samples for microbiota analyses and blood and urine samples for metabolomics analyses. Additional data collection will include dietary interviews, body weight measurements, and registration of training volume and training load. These measures will provide contextual information for the interpretation of microbiota and metabolomics data and help account for potential confounding factors.
Up to 80 participants will be included in the study. The planned sample size is based on expected changes in gut microbiota diversity reported in previous dietary intervention studies and takes anticipated participant attrition into account. The study is designed to evaluate the effects of a feasible and low-risk dietary intervention on gut microbiota diversity, microbial composition, and metabolite profiles in physically active adults.
Changes from baseline to week 4 will be compared between the intervention and control groups. Analyses will focus on measures of gut microbiota alpha diversity, microbial composition, and circulating and urinary metabolites. Repeated-measures statistical approaches will be used to account for within-participant changes over time and to evaluate differences between study groups.
The study seeks to improve understanding of the relationships among diet, gut microbiota, and systemic metabolism in physically active adults. The findings may contribute to the development of evidence-based dietary strategies aimed at supporting health, recovery, and physiological adaptation through modulation of the gut microbiota.
- Conditions
- Gut Microbiota Diversity and Composition, Gut Microbiota Modulation, Probiotic, Prebiotic, Metabolomics
- Being tested
- Barley, Kefir
- Keywords
- Gut microbiota, Gut microbiota diversity, Gut microbiota composition, Gut microbiota modulation, Dietary intervention, Barley, Kefir, Probiotic, Prebiotic, Metabolomics, Energy metabolism, Endurance exercise, Physically active adults
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BarleyOther
Daily consumption of 70 g dry weight barley for four weeks.
KefirOther
Daily consumption of 200 mL kefir for four weeks.
| Study group | Role | What they receive |
|---|---|---|
| Barley and Kefir Breakfast | Experimental | Participants will consume a standardized daily breakfast consisting of barley (70 g dry weight) and kefir (200 mL) for four weeks while maintaining their habitual diet and training routines. Receives: Other: Barley; Other: Kefir |
| Control | No intervention | Participants will maintain their habitual diet and training routines throughout the four-week study period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in gut microbiota alpha diversity.
Change in gut microbiota alpha diversity assessed by the Shannon Diversity Index using precision microbiome profiling (PMP) of stool samples.
Measured: From baseline to the end of intervention at 4 weeks.
Changes in gut microbiota composition
Change in the relative abundance of selected bacteria measured by precision microbiome profiling (PMP) of stool samples.
Measured: From baseline to end of intervention at 4 weeks
Secondary outcomes (1)
Changes in circulating metabolite concentrations
Change in concentrations of microbiome-related metabolites measured by targeted metabolomics using the Microbiome Panel (Bevital AS) in blood samples.
Measured: From baseline to end of intervention at 4 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2026
- Study start7 Sep 2026
- Primary completionJun 2031 (estimated)
- Study completionJun 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gut Microbiota Diversity and CompositionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants will be randomized using sex-stratified randomization to either an intervention group or a control group. The intervention group will consume a standardized daily breakfast consisting of barley (70 g dry weight) and kefir (200 mL) for four weeks, while the control group will maintain their habitual diet without receiving the dietary intervention. Both groups will be asked to maintain their usual dietary habits and training routines throughout the study period. Outcome measures will be assessed at baseline and after four weeks.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Western Norway University of Applied Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Iselin Thowsen Vildmyren, Western Norway University of Applied Sciences
- Investigators
- Iselin T Vildmyren, PhD, Principal investigator, Western Norway University of Applied Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07864779
- Sponsor's protocol ID
- NSD-105291
- Acronym
- GUTS
- Status last verified
- Oct 2026
- First submitted
- 23 Sep 2026
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to ethical and privacy considerations related to sensitive health information and biological specimens. Findings will be reported in aggregated form and no identifiable participant data will be made available.